Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sertraline + olanzapine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of sertraline, a selective serotonin reuptake inhibitor (SSRI), and olanzapine, an atypical antipsychotic. This combination has shown efficacy in treating negative and depressive symptoms in schizophrenia, particularly in treatment-resistant cases and first-episode patients. It has also demonstrated effectiveness in psychotic depression with lower relapse rates compared to monotherapy. The typical dosing includes low-dose olanzapine (7.5-10 mg/day) with sertraline (50-100 mg/day).
- Other names
- olanzapine + sertralinesertraline plus olanzapine
02
Targets
DRD4 (Dopamine D4 Receptor)HTR2A (Serotonin receptor 5-HT2A)SERT (Sodium-dependent serotonin transporter)CHRM5 (M5)HTR2C (5-hydroxytryptamine 2C receptor)HRH1 (Histamine H1 Receptor)M1 (Muscarinic acetylcholine receptor M1)HTR3A (5-hydroxytryptamine receptor 3A)CHRM2 (M2)DRD1 (Dopamine D1 Receptor)CHRM4 (M4)ADRB1 (β1)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)ADRA1A (α1A)GABRR (GABA-A receptor subunit rho)CHRM3 (M3)
Beyond the preview
Go deeper on sertraline + olanzapine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sertraline + olanzapine.